J&J Acquires Atraverse Medical to Bolster Cardiac Device Portfolio
JNJ sits 57% above its 52-week low of $146.115.
Summary
Johnson & Johnson announced its agreement to acquire Atraverse Medical, a privately held company specializing in next-generation left-heart access and radiofrequency technologies, including the FDA-cleared Hotwire Transseptal Access System. While financial terms were not disclosed, this strategic move aims to bolster J&J's cardiac ablation technology portfolio and help it compete in the fast-growing market for irregular heart rhythm devices. This follows recent challenges in J&J's medical device segment, including a temporary halt in U.S. sales of its Varipulse device. The acquisition signals J&J's commitment to reviving and expanding its medical device business. Traders will watch for the deal's expected Q2 close and any future disclosures on financial terms or product integration.
At the time of this announcement, JNJ was trading at $229.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $555.2B. The 52-week trading range was $146.12 to $251.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.